Cardica Completes Enrollment In European Clinical Trial For Surgical Cutting And Stapling Device

 Cardica Completes Enrollment In European Clinical Trial For Surgical Cutting
                             And Stapling Device

PR Newswire

REDWOOD CITY, Calif., May 15, 2013

REDWOOD CITY, Calif., May 15, 2013 /PRNewswire/ --Cardica, Inc. (Nasdaq:
CRDC) today announced it has completed enrollment in the European clinical
study for its MicroCutter XCHANGE™ 30, a cartridge-based cutting/stapling
device with a 5-millimeter shaft diameter and cross-sectional area more than
six times smaller than standard 12-millimeter surgical staplers used today.
The trial is designed to evaluate the safety of the XCHANGE 30 in a variety of
gastrointestinal surgical procedures to support a 510(k) filing for market
clearance from the U.S. Food and Drug Administration (FDA).

"Based on consistent product performance and positive unaudited clinical
outcomes of the trial to date, following standard statistical analyses we
expect to file regulatory documents with the FDA in the third quarter of
calendar 2013," said Bernard A. Hausen, M.D., Ph.D., president and chief
executive officer of Cardica. "We would like to express our sincere thanks to
the investigators and patients for their enthusiasm in participating in the
trial to advance the XCHANGE 30, the smallest cutting and stapling device
available today."

The prospective, single-arm, multi-center, non-inferiority clinical study
enrolled 160 patients at seven centers in Germany. The results of the
procedures will be compared to historical adverse event reports for similar
procedures performed with currently available stapling devices. Typical
adverse events associated with current surgical staplers include staple line
leakage, staple line bleeding, staple line strictures and surgical infections.

AboutCardica
Cardicadesigns and manufactures proprietary stapling and anastomotic devices
for cardiac and laparoscopic surgical procedures.Cardica's technology
portfolio is intended to minimize operating time and enable minimally-invasive
and robot-assisted surgeries. Cardica manufactures and markets its automated
anastomosis systems, the C-Port^® Distal Anastomosis Systems and PAS-Port^®
Proximal Anastomosis System for coronary artery bypass graft (CABG) surgery,
and has shipped over 45,200 units throughout the world. In
addition,Cardicais developing the Cardica^® MicroCutter XCHANGE™ 30, a
cartridge-based microcutter device with a five-millimeter shaft diameter, and
the Cardica^® MicroCutter XCHANGE™ 45, a cartridge-based microcutter device
with an eight-millimeter shaft. Both MicroCutter devices are designed to be
used in a variety of procedures, including bariatric, colorectal, thoracic and
general surgery. The Cardica MicroCutter XCHANGE 30 and XCHANGE 45 products
require 510(k) review and are not yet commercially available in the U.S.

Forward-Looking Statements
The statements in this press release regarding Cardica's expectation that it
will file regulatory documents with the FDA (510(k) filing for market
clearance) in the third quarter of calendar 2013, is a "forward-looking
statement." There are a number of important factors that could cause Cardica's
results to differ materially from those indicated by these forward-looking
statements, including: that Cardica may not be successful in its efforts to
further develop the XCHANGE 30 due to unanticipated technical or other
difficulties; that the XCHANGE 30 may face unanticipated development,
regulatory, or manufacturing delays; that Cardica's intellectual property
rights may not provide adequate protection to enable further development of
the XCHANGE 30; that surgeons may not use the XCHANGE 30 correctly, which
could cause unfavorable results that may impair the acceptance of the XCHANGE
30 by other surgeons; and that Cardica may not have sufficient funds to
develop the XCHANGE 30, as well as other risks detailed from time to time in
Cardica's reports filed with the U.S. Securities and Exchange Commission,
including its Current Report on Form 10-Q for the quarter endedDecember 31,
2012, filed with the filed with the U.S. Securities and Exchange Commission
(SEC) on February 8, 2013. Cardica expressly disclaims any obligation or
undertaking to release publicly any updates or revisions to any
forward-looking statements contained herein. You are encouraged to read
Cardica's reports filed with the SEC, available at www.sec.gov.

SOURCE Cardica, Inc.

Website: http://www.cardica.com
Contact: Bob Newell, Vice President, Finance and Chief Financial Officer,
(650) 331-7133, investors@cardica.com